Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 461-472

  Kusunoki, Yoshiki ^a   Katsuno, Tomoyuki ^a   Miyakoshi, Kana ^a   Ikawa, Takashi ^a   Nakae, Rie ^a   Ochi, Fumihiro ^a   Tokuda, Masaru ^a   Akagami, Takafumi ^a   Murai, Kazuki ^a   Miuchi, Masayuki ^a   Hamaguchi, Tomoya ^a   Miyagawa, Jun Ichiro ^a   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Basal bolus insulin therapy; Continuous glucose monitoring; Hypoglycemia; Insulin degludec; Insulin glargine or detemir; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CALORIC INTAKE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; GLYCEMIC CONTROL; HOSPITAL PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; MIDDLE AGED; NOCTURNAL HYPOGLYCEMIA; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84899882898     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0048-5     Document Type: Article

References (33)

1. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11-66.
2. Cheng AY, Zinman B. Principle of the insulin treatment. In: Kahn CR, Weir G, editors. Joslin's diabetes mellitus. 14th ed. Tokyo: Medical science international; 2007. p. 737-49 (in Japanese).
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
4. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care. 1999;22(Suppl 2):B109-13.
5. Brunner GA, Sendhofer G, Wutte A, et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes. 2000;108:100-5.
6. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-9.
7. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs. 2000;59:253-60.
8. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23:639-43.
9. Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666-71.
10. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K, Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15:369-76.
11. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care. 2001;24:296-301.
12. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005;7:73-82.
13. Mathiesen ER, Hod M, Ivanisevic M, Detemir in Pregnancy Study Group, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35:2012-7.
14. Frier BM, Russell-Jones D, Heise T. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab. 2013 (in press).
15. Albright ES, Desmond R, Bell DSH. Efficacy of conversion from bedtime NPH insulin injection to once-or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004;27:632-3.
16. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104-14.
17. Novo Nordisk Pharm Ltd. (Internal company data). http://www.novonordisk.co.jp (last accessed November 15, 2013)
18. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379: 1489-97.
19. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-71.
20. Iwamoto Y, Clauson P, Nishida T, Kaku K. Insulin degludec in Japanese patients with type 1 diabetes mellitus: a randomized controlled trial. J Diabetes Investig. 2013;4:62-8.
21. Hirsch IB, Bode B, Courreges JP, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012;35:2174-81.
22. Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN() Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013;30:1293-7.
23. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98: 1154-62.
24. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669-74.
25. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290-9.
26. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008;25:442-9.
27. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther. 2009;31:2086-97.
28. Kawamori R, Iwamoto Y, Kadowaki T, Iwasaki M. Comparison of efficacy between insulin glargine and NPH human insulin in type l diabetes patients undergoing intensive insulin treatment. J Clin Ther Med. 2003;19(5):423-44 (in Japanese).
29. Kobayashi M, Iwamoto Y, Kaku K, et al. 48-week randomized multicenter open-label parallel group phase 3 trial to compare insulin detemir and NPH insulin efficacy and safety in subjects with insulin requiring diabetes mellitus in a basal-bolus regimen. J Japan Diabetes Soc. 2007;50:649-63 (in Japanese).
30. Hashimoto T, Kawamura T, Kashihara Y, et al. Factors associated with basal insulin dose in Japanese children and young adult type 1 diabetics. J Diabetes Investig. 2012;3:276-82.
31. Katsuno T, Hamaguchi T, Nagai E, et al. Influence of insulin glargine on basal insulin supplementation in Japanese Type 1 diabetic patients treated with basal-bolus injection therapy. J Japan Diabetes Soc. 2008;51:983-90 (in Japanese).
32. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care. 1993;16(Suppl 3):71-89.
33. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabetes Med. 2006;23:879-86.